• Recruiting

NCT04674813: Phase 1 - A Study of CC-95266 in Subjects With Relapsed and/or Refractory Myeloma

Updated: Sep 2

A Study of CC-95266 in Subjects With Relapsed and/or Refractory Multiple Myeloma

CC-95266

This is a Phase 1, multicenter, open label, study of CC-95266 in subjects with relapsed and/or refractory multiple myeloma. The study will consist of two parts: dose escalation (Part A) and dose expansion (Part B). The dose escalation (Part A) of the study will evaluate the safety and tolerability of increasing doses of CC-95266 in a single administration to establish a maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D), and the dose expansion (Part B) of the study will further evaluate the safety, pharmacokinetics (PK)/ pharmacodynamics (PD), and efficacy of CC-95266 at the RP2D.


Sponsor

Juno Therapeutics, a Subsidiary of Celgene


Multiple Locations

 

ClinicalTrials.gov Identifier: NCT04674813


Official Title: A Phase 1, Multicenter, Open-Label Study of CC-95266 in Subjects With Relapsed and/or Refractory Multiple Myeloma


First Posted : December 19, 2020


Click here for details on ClinicalTrials.gov


Click here for details on cancer.gov

 

CC-95266

Multi-center phase I of GPRC5D-Targeted CARs

 

Drug: CC-95266

Drug: Fludarabine

Drug: Cyclophosphamide

 

- Colorado: Sarah Cannon/Colorado Blood Cancer Institute Denver

- Massachusetts: Dana-Farber Cancer Institute/Harvard Cancer Center Boston

- New York: Tisch Cancer Institute Mount Sinai Hospital New York

- Tennessee: Sarah Cannon Research Institute Nashville

- Texas: UT Southwestern Medical Center Dallas

 

Locations

United States, Alabama

United States, California

United States, Colorado

United States, Maryland

United States, Massachusetts

United States, New York

United States, Tennessee

United States, Texas

United States, Washington


Posts Archive